We are at a crisis point
in mental health provision.
Mental health and addiction (including alcohol), is the 5th leading cause of illness globally, affecting 20% of the world’s population.
Unlike other medical disciplines, psychiatry focuses on maintenance rather than cure, and symptom suppression rather than addressing the root causes of these illnesses.
The exception is Psychedelics and Psychedelic-Assisted Psychotherapy which have the potential to radically change mental health services and deliver significantly better patient outcomes.
About Awakn
Awakn Life Sciences is a biotechnology company focused on research, development, and delivery of psychedelic medicines for the treatment of mental health conditions.
We are creating a paradigm shift in psychiatry by integrating psychedelic medicine into mainstream mental healthcare with a strategic focus on the treatment of Addiction, Anxiety, Depression and PTSD across three business divisions of Research, Clinics and Platforms.
We have a dual strategic focus of developing and commercialising psychedelic intellectual property focused on treating addiction, and treating Addiction, Anxiety, Depression, and PTSD through a chain of medical psychedelic clinics.
Our goals are to be a global leader in psychedelic clinical research for treatment of addiction, to operate the UK and EU’s leading chain of medical psychedelic clinics, and to drive lasting systemic change for patients and society through our Psychedelic Healthcare Services Platform.
Why Awakn
➀
The leading scientific and medical team in the industry
Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Prof. Matt Johnson, Dr. Michael Mithoefer, and Ann Mithoefer
➁
Global research leaders in psychedelic treatments
Dr. Ben Sessa has led the world’s only MDMA and AUD study (BIMA) and Prof. Celia Morgan has led the world’s leading Ketamine AUD study (KARE)
➂
Strategic partnerships
Strategic partnerships with two leading UK universities for exclusive access to data and findings from recent clinical trials
➃
Clear IP development pathway
• Phase II trial for MDMA and AUD starting in 2021
• Patents filed for psychedelic methods of treatment for AUD
➄
Scalable Revenue Streams
• Clinic revenue starting in Q1 2021
• Licensed Methods of Treatment 2022 onwards
➅
Significant first mover advantage in UK and EU
400m people and US$19trn GDP
Divisions
Our business consistent of three related and compilatory divisions: Research, Clinics, and Platforms.
Research
Our team has led clinical trials and research that have defined the psychedelic medicine industry, including: the Bristol Imperial MDMA for Alcoholism (BIMA) study and the Ketamine for Reduction of Alcoholic Relapse (KARE).
We have a portfolio of clinical research and trials planned and initiated focused on treating addiction.
Clinics
We utilise the effects of the acute drug state induced by psychedelics alongside a course of psychotherapy to treat a range of mental health issues including Addiction, Anxiety, Depression, and PTSD.
• Bristol Q1 2021
• London & Manchester 2021
• Edinburgh, Brighton, Birmingham 2022
• EU 2023+
Platforms
We are driving lasting systemic change for patients and society
• Training
• Licensing
• Data & Analytics
Scientific Advisory Team
Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry
Prof. David Nutt
CHAIR
Dr. Ben Sessa
CHIEF MEDICAL OFFICER
Prof. Celia Morgan
HEAD OF KETAMINE-ASSISTED
PSYCHOTHERAPY FOR ALCOHOL
USE DISORDER PRACTICE
Dr. Michael Mithoefer
ADVISOR
Ann Mithoefer, BSN
ADVISOR
Prof. Matthew W. Johnson
ADVISOR
Leadership Team
Dr. Ben Sessa
CHIEF MEDICAL OFFICER
Prof. Celia Morgan
HEAD OF KETAMINE-ASSISTED
PSYCHOTHERAPY FOR ALCOHOL
USE DISORDER PRACTICE
Dr. Laurie Higbed
LEAD PSYCHOLOGIST
George Scorsis
CHAIR
Anthony Tennyson
CHIEF EXECUTIVE OFFICER
James Collins
CHIEF OPERATING OFFICER
Dr. Shaun McNulty
CHIEF SCIENCE OFFICER
Jonathan Held
CHIEF FINANCIAL OFFICER
Latest News
Video Resources
Dr. Ben Sessa: TEDx
Michael Pollan: Psychedelics solve mental health crisis
Revealing the Mind: The Promise of Psychedelics
Prof. David Nutt: TEDx
Contact
MAIN OFFICE
Suite 200, 366 Bay St, Toronto, Ontario, M5H 4B2, Canada
Ⓔ info@awaknlifesciences.com
UK OFFICE
1 Regents Street, Bristol, BS8 4HW, United Kingdom
Ⓔ clinics@awaknlifesciences.com
For all enquiries, complete the form and we’ll be in touch.
© 2020 Awakn Life Sciences Inc